Abstract CT241: Phase 2 window of opportunity trial of pyrimethamine in locoregionally advanced head and neck squamous cell carcinoma

Paul Zolkind(Washington University in St. Louis), Michael B. Major(Washington University in St. Louis), Ryan S. Jackson(Washington University in St. Louis), Sidharth V. Puram(Washington University in St. Louis), Anthony J. Apicelli(Washington University in St. Louis), Emily Wilkerson(Washington University in St. Louis), Patrik Pipkorn(Washington University in St. Louis), Julius Chembo(Washington University in St. Louis), Harit Panda(Washington University in St. Louis), Wade L. Thorstad(Washington University in St. Louis), Jennifer De Los Santos(University of Alabama at Birmingham), Michael Atteberry(Washington University in St. Louis), Kynlee Giesie(Washington University in St. Louis), Kate Zhao(Washington University in St. Louis), Alex Harbison(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), James Sun(Washington University in St. Louis), Sidra Major(Washington University in St. Louis), Luke Chen(Coriell Institute For Medical Research), Douglas Adkins(Washington University in St. Louis), Jessica Ley(Washington University in St. Louis), Peter Oppelt(Washington University in St. Louis), Nathan Wamsley(Washington University in St. Louis)
Cancer Research
April 17, 2026
Cited by 0


Related Papers